MMWR. Morbidity and mortality weekly report最新文献

Erratum: Vol. 74, No. RR-1. 勘误：第74卷，第7号。RR-1。

IF 17.3 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2025-09-18 DOI: 10.15585/mmwr.mm7435a3

引用次数: 0

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025-26 Influenza Season. 用疫苗预防和控制季节性流感：免疫实践咨询委员会的建议——美国，2025-26年流感季节

IF 17.3 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2025-08-28 DOI: 10.15585/mmwr.mm7432a2

Lisa A Grohskopf, Lenee H Blanton, Jill M Ferdinands, Carrie Reed, Vivien G Dugan, Demetre C Daskalakis

{"title":"Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025-26 Influenza Season.","authors":"Lisa A Grohskopf, Lenee H Blanton, Jill M Ferdinands, Carrie Reed, Vivien G Dugan, Demetre C Daskalakis","doi":"10.15585/mmwr.mm7432a2","DOIUrl":"10.15585/mmwr.mm7432a2","url":null,"abstract":"This report updates the 2024-25 recommendations of the Advisory Committee on Immunization Practices (ACIP) concerning the use of seasonal influenza vaccines in the United States. Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have a contraindication to vaccination. Multiple formulations of the trivalent inactivated influenza vaccines (IIV3s), trivalent recombinant influenza vaccine (RIV3), and trivalent live attenuated influenza vaccine (LAIV3) are expected to be available for the 2025-26 influenza season. Updates for the 2025-26 season include 1) antigenic composition of 2025-26 U.S. seasonal influenza vaccines, 2) Food and Drug Administration (FDA) approval of FluMist (LAIV3) for self-administration or caregiver administration, 3) FDA approval of a change in age indication for Flublok (RIV3) from ≥18 years to ≥9 years, and 4) a new ACIP recommendation that children aged ≤18 years, pregnant women, and all adults receive seasonal influenza vaccines only in single-dose formulations that are free of thimerosal as a preservative. A comprehensive summary of recommendations, including those discussed in this report, as well as previous recommendations concerning topics not addressed in this report and that remain unchanged for the 2025-26 season, is available at Influenza | ACIP Recommendations for Vaccination. Additional background information also is available at Prevention and Control of Seasonal Influenza with Vaccines.","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"74 32","pages":"500-507"},"PeriodicalIF":17.3,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12393693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144961081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025. 使用Clesrovimab预防婴儿严重呼吸道合胞病毒相关下呼吸道感染：免疫实践咨询委员会的建议-美国，2025。

IF 17.3 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2025-08-28 DOI: 10.15585/mmwr.mm7432a3

Danielle L Moulia, Ruth Link-Gelles, Helen Y Chu, Denise Jamieson, Oliver Brooks, Sarah Meyer, Eric S Weintraub, David K Shay, Mila M Prill, Ebony S Thomas, David Hutton, Ismael R Ortega-Sanchez, Adam MacNeil, Meredith L McMorrow, Jefferson M Jones

{"title":"Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025.","authors":"Danielle L Moulia, Ruth Link-Gelles, Helen Y Chu, Denise Jamieson, Oliver Brooks, Sarah Meyer, Eric S Weintraub, David K Shay, Mila M Prill, Ebony S Thomas, David Hutton, Ismael R Ortega-Sanchez, Adam MacNeil, Meredith L McMorrow, Jefferson M Jones","doi":"10.15585/mmwr.mm7432a3","DOIUrl":"10.15585/mmwr.mm7432a3","url":null,"abstract":"Before the introduction of universal respiratory syncytial virus (RSV) immunization recommendations for infants, RSV was the leading cause of hospitalization among infants in the United States. Since 2023, CDC's Advisory Committee on Immunization Practices (ACIP) has recommended that all infants be protected against RSV-associated lower respiratory tract infection (LRTI) through either 1) maternal RSV vaccination during pregnancy (Abrysvo, Pfizer) or 2) administration of nirsevimab (Beyfortus, Sanofi and AstraZeneca), a long-acting RSV monoclonal antibody, to the infant. In June 2025, the Food and Drug Administration licensed clesrovimab (Enflonsia, Merck), a second long-acting RSV monoclonal antibody, for prevention of RSV-associated LRTI in infants. Since September 2024, the ACIP Maternal/Pediatric RSV Work Group has reviewed evidence regarding the safety and efficacy of clesrovimab use in infants. On June 26, 2025, ACIP recommended clesrovimab as a second long-acting monoclonal antibody product that could be used as an alternative to nirsevimab for prevention of RSV-associated LRTI among infants aged <8 months who are born during or entering their first RSV season and who are not protected through maternal RSV vaccination. All infants should be protected against RSV-associated LRTI through use of one of these three products (i.e., maternal RSV vaccination or administration of nirsevimab or clesrovimab to the infant). No one product is preferred; the choice should be guided by parent preference, product availability, and timing of the infant's birth relative to the RSV season.","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"74 32","pages":"508-514"},"PeriodicalIF":17.3,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12393692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144961104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug Overdose Deaths Involving Stimulants - United States, January 2018-June 2024. 涉及兴奋剂的药物过量死亡-美国，2018年1月至2024年6月。

IF 17.3 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2025-08-28 DOI: 10.15585/mmwr.mm7432a1

Lauren J Tanz, Kimberly D Miller, Amanda T Dinwiddie, R Matt Gladden, Alice Asher, Grant Baldwin, Brandon Nesbit, Julie O'Donnell

{"title":"Drug Overdose Deaths Involving Stimulants - United States, January 2018-June 2024.","authors":"Lauren J Tanz, Kimberly D Miller, Amanda T Dinwiddie, R Matt Gladden, Alice Asher, Grant Baldwin, Brandon Nesbit, Julie O'Donnell","doi":"10.15585/mmwr.mm7432a1","DOIUrl":"10.15585/mmwr.mm7432a1","url":null,"abstract":"Drug overdose deaths involving stimulants have increased in the United States since 2011. This report describes characteristics of stimulant-involved overdose deaths during January 2021-June 2024 using CDC's State Unintentional Drug Overdose Reporting System data and trends by drug and race and ethnicity during 2018-2023 using CDC's National Vital Statistics System data. Overall, 59.0% of overdose deaths involved stimulants, 43.1% co-involved stimulants and opioids, and 15.9% involved stimulants and no opioids during January 2021-June 2024. Persons who died of overdoses involving stimulants and no opioids were older (aged ≥45 years; 66.5% versus 44.2%) and more frequently had a history of cardiovascular disease (38.7% versus 21.2%) than those who died of overdoses involving stimulants and opioids. Stimulant-involved overdose death rates increased from 2018 to 2023 (cocaine: 4.5 per 100,000 population to 8.6; psychostimulants with abuse potential, primarily methamphetamine: 3.9 to 10.4). Increases were largest for psychostimulants among non-Hispanic American Indian or Alaska Native persons (11.0 in 2018 to 32.9 in 2023) and cocaine among non-Hispanic Black or African American persons (9.1 to 24.3), driven by deaths co-involving stimulants and opioids. Increases in stimulant-involved deaths suggest the need for expanded access to evidence-based stimulant use disorder treatments, evaluation of medication-based treatments for stimulant use disorder and treatments for co-occurring substance use disorders, and engagement of persons who use stimulants and who might be missed by opioid-focused prevention efforts.","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"74 32","pages":"491-499"},"PeriodicalIF":17.3,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12393691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144961015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reoccurring Salmonella Cotham Outbreak Linked to Pet Bearded Dragons - United States, 2024. 与宠物胡须龙有关的反复发生的科瑟姆沙门氏菌爆发-美国，2024年。

IF 17.3 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2025-08-21 DOI: 10.15585/mmwr.mm7431a1

Lingzi Xiaoli, Paula Huth, Cassandra Sherman, Danielle Wroblewski, Stacy Anderson, Lindsey Ferraro, Dee Jones, Molly Slaughter, Brenda Morningstar, Tonya Mackie, Natalee Bowen, Molly Leeper, Katie Werner, Katharine Benedict, Kate Varela

{"title":"Reoccurring Salmonella Cotham Outbreak Linked to Pet Bearded Dragons - United States, 2024.","authors":"Lingzi Xiaoli, Paula Huth, Cassandra Sherman, Danielle Wroblewski, Stacy Anderson, Lindsey Ferraro, Dee Jones, Molly Slaughter, Brenda Morningstar, Tonya Mackie, Natalee Bowen, Molly Leeper, Katie Werner, Katharine Benedict, Kate Varela","doi":"10.15585/mmwr.mm7431a1","DOIUrl":"https://doi.org/10.15585/mmwr.mm7431a1","url":null,"abstract":"In April 2024, CDC's PulseNet identified a cluster of seven Salmonella Cotham cases from five states. Isolates were highly related by whole genome sequencing (WGS), and one patient reported contact with a pet bearded dragon. CDC initiated a multistate investigation and as of December 10, 2024, an additional 19 cases had been identified, for a total of 26 confirmed cases from 13 states; state public health partners identified one probable case in an additional state for a total of 27 cases. Eighteen of 25 cases (72%) were among persons who reported contact with a bearded dragon or lizard. Children aged <5 years, especially infants, were disproportionately affected, accounting for 17 (65%) of the 26 confirmed cases; most had bearded dragons in the home without direct animal contact. WGS of two bearded dragon specimens collected in 2024 and three bearded dragon specimens collected during 2012-2014 confirmed genetic relatedness of this rare Salmonella strain and continued circulation among commercially sold bearded dragons. CDC implemented a One Health approach in response, working with pet industry representatives to disseminate information about biosecurity best practices to bearded dragon suppliers and retailers. Investigators contacted a common bearded dragon supplier identified in the traceback investigation to share biosecurity and prevention recommendations. CDC used social media and a website investigation notice to inform the public, recommending that caregivers prevent young children from indirect reptile contact by restricting reptiles from roaming freely, separating reptiles and supplies from food preparation areas, and washing hands and changing clothes after handling reptiles and before holding infants.","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"74 31","pages":"474-479"},"PeriodicalIF":17.3,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12370015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144961009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination - United States, October 2023-March 2024. 通过接受尼塞维单抗单克隆抗体或母亲接种疫苗，婴儿呼吸道合胞病毒免疫覆盖率-美国，2023年10月至2024年3月

IF 17.3 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2025-08-21 DOI: 10.15585/mmwr.mm7431a3

Ellen O Boundy, Hannah Fast, Tara C Jatlaoui, Hilda Razzaghi, LaTreace Harris, Kimberly Nguyen, Jamie Mells, Georgina Peacock, Carla L Black

{"title":"Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination - United States, October 2023-March 2024.","authors":"Ellen O Boundy, Hannah Fast, Tara C Jatlaoui, Hilda Razzaghi, LaTreace Harris, Kimberly Nguyen, Jamie Mells, Georgina Peacock, Carla L Black","doi":"10.15585/mmwr.mm7431a3","DOIUrl":"https://doi.org/10.15585/mmwr.mm7431a3","url":null,"abstract":"Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization in the United States. A new RSV monoclonal antibody (nirsevimab) for infants and an RSV vaccine for pregnant women were recommended by the Advisory Committee on Immunization Practices in August and September 2023, respectively, to protect infants against RSV infection. Sufficient data have become available to allow estimates of infant RSV immunization coverage through administration of these products. Among infants born during October 2023-March 2024, infant RSV immunization coverage was estimated by summing the total number of infants who received nirsevimab and the number of women of childbearing age who received RSV vaccine, as reported to immunization information systems (IISs) in 33 U.S. states and the District of Columbia (DC), and dividing by the total number of live births, obtained from CDC Wide-ranging Online Data for Epidemiologic Research (WONDER) natality data. Across 33 states and DC, an estimated 29% of infants born during October 2023-March 2024 were immunized against RSV during the 2023-24 respiratory virus season, including 19% through infant receipt of nirsevimab and 10% through maternal RSV vaccination. Infant RSV immunization coverage through nirsevimab or maternal vaccination ranged from an estimated 11% to 53% by state. Among infants who received nirsevimab, 38% received it within the first week of life (0-6 days after birth). Continued efforts are needed to increase RSV immunization coverage among infants and pregnant women.","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"74 31","pages":"484-489"},"PeriodicalIF":17.3,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12370014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144961096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rabies Outbreak in an Urban, Unmanaged Cat Colony - Maryland, August 2024. 2024年8月，马里兰州一个城市无管理的猫群爆发狂犬病。

IF 17.3 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2025-08-21 DOI: 10.15585/mmwr.mm7431a2

Sarah Ludmer, David Crum, Ryan Wallace, Jeré Hutson

{"title":"Rabies Outbreak in an Urban, Unmanaged Cat Colony - Maryland, August 2024.","authors":"Sarah Ludmer, David Crum, Ryan Wallace, Jeré Hutson","doi":"10.15585/mmwr.mm7431a2","DOIUrl":"https://doi.org/10.15585/mmwr.mm7431a2","url":null,"abstract":"Exposure to a rabid animal is a life-threatening emergency because infection is almost always fatal if rabies postexposure prophylaxis (PEP) is not initiated promptly. In August 2024, the Maryland Department of Health was notified that an aggressive feral cat had been captured and euthanized and had subsequently received a positive test result for rabies. The cat was part of a group of approximately 20 local feral cats and kittens that was receiving no, or little, human care (i.e., an unmanaged cat colony). Cecil County (Maryland) Health Department and the Maryland Department of Health coordinated with Cecil County Animal Services, Cecil County Emergency Services, and CDC to identify and interview persons potentially exposed to the rabid cat, which included a novel use of reverse 911 messaging. Three persons were identified who had been exposed, and all received PEP. No human rabies cases occurred. Three additional cats from the colony were captured and euthanized; their rabies test results were negative. Unmanaged cat colonies pose public health risks, and extensive resources might be required to prevent negative health outcomes. Cat colony management, including activities to maintain high rabies vaccination coverage within colonies, can help to mitigate these risks. A better understanding of urban cat ecology and its role in rabies transmission and human exposure is needed.","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"74 31","pages":"480-483"},"PeriodicalIF":17.3,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12370016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144961040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaccination Coverage Among Adolescents Aged 13-17 Years - National Immunization Survey-Teen, United States, 2024. 13-17岁青少年的疫苗接种覆盖率——2024年美国全国免疫调查

IF 17.3 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2025-08-14 DOI: 10.15585/mmwr.mm7430a1

Cassandra Pingali, David Yankey, Laurie D Elam-Evans, Adam Trahan, Lauri E Markowitz, Carla L DeSisto, Michelle Hughes, Madeleine R Valier, Shannon Stokley, James A Singleton

{"title":"Vaccination Coverage Among Adolescents Aged 13-17 Years - National Immunization Survey-Teen, United States, 2024.","authors":"Cassandra Pingali, David Yankey, Laurie D Elam-Evans, Adam Trahan, Lauri E Markowitz, Carla L DeSisto, Michelle Hughes, Madeleine R Valier, Shannon Stokley, James A Singleton","doi":"10.15585/mmwr.mm7430a1","DOIUrl":"10.15585/mmwr.mm7430a1","url":null,"abstract":"Three vaccines are recommended for routine administration to adolescents by the Advisory Committee on Immunization Practices: tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap); quadrivalent meningococcal conjugate vaccine (MenACWY); and human papillomavirus (HPV) vaccine. Data from the 2024 National Immunization Survey-Teen were analyzed to determine national, state, and selected local area vaccination coverage in 2024. Household response rate (21.0%) and receipt of adequate provider data for adolescents with completed interviews (42.8%) were comparable to prior survey years. Among 16,325 adolescents aged 13-17 years with adequate provider data included in the survey, coverage with ≥1 Tdap dose increased from 89.0% in 2023 to 91.3% in 2024; coverage with ≥1 MenACWY dose increased from 88.4% to 90.1%. HPV vaccination coverage remained stable for the third consecutive year; 78.2% of adolescents had received ≥1 dose, and 62.9% were up to date with the HPV vaccination series. Coverage with ≥1 Tdap dose was ≥90% in 39 states, with ≥1 MenACWY dose was ≥90% in 30 states, and with ≥1 dose of HPV vaccine was ≥80% in 26 states and the District of Columbia. Since 2016, lower HPV vaccination coverage in nonmetropolitan statistical areas (MSAs) compared with that in MSA principal cities has persisted, with an 11 percentage point difference in coverage with ≥1 HPV vaccine dose and percentage of adolescents up to date with HPV vaccination in 2024. Health care providers can support adolescent health by discussing and recommending vaccines, as well as reviewing patient records to ascertain whether adolescents are up to date with recommended vaccines.","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"74 30","pages":"466-472"},"PeriodicalIF":17.3,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12352626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum: Vol. 73, No. 41. 勘误：第73卷，第41号。

IF 25.4 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2025-07-10 DOI: 10.15585/mmwr.mm7425a3

引用次数: 0

Erratum: Vol. 74, No. 18. 勘误：第74卷，第18号。

IF 25.4 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2025-07-10 DOI: 10.15585/mmwr.mm7425a2

引用次数: 0